Novo Nordisk will sell Wegovy and Ozempic drugs through the telehealth company Hims & Hers.
Novo Nordisk and Hims & Hers have reached a deal that, for now, appears to end their bitter dispute around Hims’ sale of compounded versions of Novo’s blockbuster obesity drug Wegovy.
The price of the company's popular GLP-1 drugs could come down by as much as 50% next year.
Ozempic maker's lawsuit, FDA enforcement could curtail sales of less expensive, compounded, versions of popular weight loss drugs.
Feb 23 (Reuters) - Novo Nordisk shares slumped by more than 16% on Monday, wiping away the remaining gains brought by its blockbuster weight-loss drug Wegovy, after the drugmaker said its ...
Novo Nordisk A/S (NYSE: NVO) plans to start selling its blockbuster obesity drug Wegovy in vials, marking its latest effort to strengthen its position against rival Eli Lilly and Co. (NYSE: LLY) as ...
Hosted on MSN
Novo to follow Lilly and sell obesity shot in vials
(Bloomberg) -- Novo Nordisk A/S aims to start selling its weight-loss blockbuster Wegovy in vials, its latest move to win over customers it’s lost to rival Eli Lilly & Co. Currently Novo sells the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results